Sugi Predict

Sugi Predict / Compounds / SCHEMBL2071987

SCHEMBL2071987

SCHEMBL2071987

CC(C)(C)OC(=O)N1CCCCC(CO)C1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.57
▸ HPGD P15428 1/20 0.52
▸ MEN1 O00255 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ BACE1 P56817 2/20 0.47
▸ CTSD P07339 1/20 0.47
▸ EPHX1 P07099 1/20 0.47
▸ GLS O94925 2/20 0.47
▸ ACKR3 P25106 1/20 0.45
▸ PREP P48147 2/20 0.45
▸ KDM1A O60341 1/20 0.43
▸ FEN1 P39748 1/20 0.43
▸ SCN9A Q15858 1/20 0.43
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31421369 1.00 NR1H2 (0.57) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL31421589 1.00 NR1H2 (0.57) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL1785894 0.95 NR1H2 (0.59) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL344915 0.95 NR1H2 (0.59) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL344916 0.95 NR1H2 (0.59) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL621267 0.89 NR1H2 (0.62) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL514696 0.89 NR1H2 (0.62) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL515486 0.89 NR1H2 (0.62) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL7448268 0.89 NR1H2 (0.52) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL16925474 0.88 HPGD (0.52) NR1H2HPGDMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4294800-B1 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS INC (US) 2026-05-06 — — EP disclosed
US-12570672-B2 Macrocyclic compounds and methods of use AMGEN INC. 2026-03-10 — — US disclosed
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-04 — — US disclosed
US-20250304599-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2025-10-02 — — US disclosed
EP-4598921-A1 MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE Amgen Inc. (US) 2025-08-13 — — EP disclosed
US-20250236631-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2025-07-24 — — US disclosed
EP-4540254-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2024249252-A1 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
US-20240316038-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-09-26 — — US disclosed
US-20240294551-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2024-09-05 — — US disclosed
US-20150197533-A1 AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS NOVIRA THERAPEUTICS, INC. 2015-07-16 — — US disclosed
US-20150197533-A1 AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS NOVIRA THERAPEUTICS, INC. 2015-07-16 — — US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 — — US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 — — US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 — — US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 — — US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 — — US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 — — US disclosed
EP-1780210-A1 NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2007-05-02 — — EP disclosed
EP-1780210-A1 NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2007-05-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236631-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE KRAS, NRAS, HRAS NR1H2 1553/4885HPGD 1367/4885MEN1 166/4885
US-12570672-B2 Macrocyclic compounds and methods of use KRAS, NRAS, BRAF NR1H2 2728/4885HPGD 2567/4885MEN1 34/4885
US-20250304599-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE KRAS, NRAS, HRAS NR1H2 1553/4885HPGD 1367/4885MEN1 166/4885
US-20240294551-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE KRAS, NRAS, HRAS NR1H2 1553/4885HPGD 1367/4885MEN1 166/4885
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS NR1H2 2340/4885HPGD 696/4885MEN1 948/4885
US-20150197533-A1 AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS HAVCR2, HDGF, AZI2 NR1H2 14/4885HPGD 171/4885MEN1 3142/4885
US-20240316038-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, SAAL1, APOB NR1H2 17/4885HPGD 4197/4885MEN1 1930/4885
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative PPARA, PPARG, PPARD NR1H2 62/4885HPGD 2412/4885MEN1 3887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.